Effect of Natalizumab Treatment on Circulating Plasmacytoid Dendritic Cells: A Cross-Sectional Observational Study in Patients with Multiple Sclerosis
Figure 4
In vitro effects of natalizumab treatment on plasmacytoid dendritic cells.
Effects of natalizumab (NTZ) treatment on plasmacytoid dendritic cells (PDCs) stimulated in vitro with CpG-containing oligonucleotides (open: ODN-2006; gray: ODN-2336). (A) PDCs were isolated from healthy controls using FACS sorting and stimulated in the presence of 15 µg/ml of NTZ or an isotype control for 4 hours. The expression of CD49d, IL-6, IL-12 (p35), TNF, TLR9, CD80, HLA-DR, and CCR7 mRNA was determined using rt-PCR. (B) Total PBMCs were stimulated in the presence of 15 µg/ml of NTZ or an isotype control for 18 hours. Surface expression of CD49d, CD40, CD80, CD83, CD86, CCR7, and HLA-DR was determined on PDCs using flow cytometry. Graphs shows fold change in expression comparing cultures treated with NTZ to cultures treated with an isotype control.